Analyst Price Targets — GKOS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 2:04 pm | — | Truist Financial | $180.00 | $159.17 | TheFly | Glaukos price target raised to $180 from $160 at Truist |
| July 13, 2026 11:19 am | — | BTIG | $164.00 | $152.72 | TheFly | Glaukos price target raised to $164 from $162 at BTIG |
| July 6, 2026 10:04 am | — | H.C. Wainwright | $168.00 | $148.34 | TheFly | Glaukos initiated with a Buy at H.C. Wainwright |
| June 17, 2026 10:07 am | David Saxon | Needham | $150.00 | $127.53 | StreetInsider | Glaukos Corporation (GKOS) PT Raised to $150 at Needham |
| May 21, 2026 9:34 am | Ryan Zimmerman | BTIG | $162.00 | $143.82 | StreetInsider | Glaukos Corporation (GKOS) PT Raised to $162 at BTIG |
| April 30, 2026 12:27 pm | Thomas Stephan | Stifel Nicolaus | $170.00 | $135.57 | TheFly | Glaukos price target raised to $170 from $160 at Stifel |
| April 30, 2026 11:24 am | — | BTIG | $141.00 | $116.96 | TheFly | Glaukos price target raised to $141 from $131 at BTIG |
| April 30, 2026 11:16 am | — | Needham | $136.00 | $116.96 | TheFly | Glaukos price target raised to $136 from $127 at Needham |
| February 18, 2026 12:18 pm | David Saxon | Needham | $127.00 | $106.64 | TheFly | Glaukos price target raised to $127 from $125 at Needham |
| February 18, 2026 11:25 am | — | Wells Fargo | $135.00 | $106.64 | TheFly | Glaukos price target raised to $135 from $122 at Wells Fargo |
Latest News for GKOS
Alex R. Thurman generated ~$1.6 million in gross proceeds by selling 10,000 shares at $155 per share on July 9. The disposition represented 19% of the insider's total equity holdings, including shares acquired through a concurrent option exercise.
Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized focus on disruptive ophthalmic technologies for glaucoma and corneal care.
GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.
This medical stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest earnings report.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company's management will discuss the results during a conference call and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GKOS.
U.S. House Trading
No House trades found for GKOS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.